Lonza Group Ltd

LONN: XSWX (CHE)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
CHF 398.00KzjmlZmzrggfm

Narrow-Moat Lonza Benefits From Strong Biologics Demand; Positive Long-Term Outlook

Business Strategy and Outlook

Lonza Group has been a dominant player in the contract development and manufacturing space for decades. We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more complex with biologics and cell and gene therapies playing larger roles in the overall mix.

Sponsor Center